anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To industrially advantageously and inexpensively obtain ultra-fine particles having high resistance to light, in which organic components are free from deterioration by coating the surface of each fine product obtained by hydrolyzing an aqueous solution of titanium tetrachloride with an alkoxysilane compound or an aminoalkoxysilane compound. SOLUTION: Fine particulate titania sol in which each particle has rutile nucleus is prepared by heating an aqueous solution containing titanium tetrachloride in an amount of about 150 200 g/l expressed in terms of TiO2, at a temp., e.g. at about 85 deg.C to the boiling point for about 2 to 10 h to hydrolyze it. The surface of the product thus hydrolyzed having an average primary particle diameter of <=0.03 μm is coated with an amount of 1 to 50 wt.% of an alkoxysilane compound and/or aminoalkoxysilane compound. Optionally, the surface of the hydrolyzed product is coated with the compound after being heat-treated at 100 to 600 deg.C. As the alkoxysilane compound, n- hexyltrimethoxysilane is preferable, and as the aminoalkoxysilane compound, γ-aminopropyltrimethoxysilane or γ-aminopropyltriethoxysilane is preferable.
The study provides a collection of retrospective data from adult patients with ultra-rare inherited neurological diseases followed at "Carlo Besta" Neurological Institute from 1st January 2004 until March 2021. Further, prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years. Normal clinical practice will be followed for collection of the prospective data. Follow-up assessment will be performed at least once a year to evaluate the disease course. Based on their clinical manifestations, patients will be assessed by using quantitative functional tests (clinimetric tests such as Timed Up and Go Test) and traditional ordinal scales (such as the scale for the assessment and rating of ataxia (SARA). Moreover, a varying of laboratory and instrumental tests (e.g., neuroimaging, neurophysiological investigations, etc.) will be used according to clinical practice in selected patients.
Hypertension and atrial fibrillation are 2 important public health priorities. There is a gap between evidence-based best management and actual clinical practice. To decrease this gap, clinical practice guidelines (CPGs), based on available evidence are employed. Clinical decision support system ("MedicBK") is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care. The INTELLECT II trial is designed as a multicenter, cluster-randomized, single-blind, controlled study with blinded outcome assessment. Approximately 10 centers from Russia will be enrolled. Centers managing patients with symptomatic atrial fibrillation and/or hypertension will be randomized to either patient management with aid of CDSS ("MedicBK") or standard care.
There will be 8 total treatments. These will follow the manufacturer protocol of 2 injections 24-72 hours apart (one cycle), followed by a 6-week break. This will total a maximum of 4 cycles.
The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
BACKGROUND: The long-term risk of pouch failure after restorative proctocolectomy with ileal-pouch anal anastomosis (IPAA) range from 5% to 15%. Salvage surgery for failing IPAA may be achieved by disconnecting the IPAA and either repairing and reusing the existing pouch (REP) or constructing a neopouch (NEO). We aimed to evaluate whether there are differences in long-term functional pouch survival and functional outcomes between the REP group and the NEO group. We hypothesized that patients undergoing REP have higher long-term pouch survival rates compared with patients who require NEO pouch construction.
STUDY DESIGN: Our prospectively maintained Pouch Registry was queried for patients who underwent a pouch salvage surgery with either pouch REP or NEO from 1988 to 2020. Patients who underwent pouch repair without disconnection from the anus were excluded. The primary endpoint was long-term pouch survival after redo pouch surgery. Secondary outcomes were patient-reported quality of life and pouch function.
RESULTS: Of 653 patients undergoing redo IPAA, 462 met inclusion criteria of transabdominal redo surgery with pouch reconnection: 243 (52.6%) had REP and 219 (47.4%) had NEO. Median age was 39 years and 59% were women. Median time between index and redo IPAA was 34 months for REP vs 54 months for NEO (p = 0.002). The 5-year pouch survival after redo IPAA was similar between REP (79.5%) and NEO (76.8%) groups (p = 0.4). Fewer patients in the REP group reported nighttime pad use (51.4% vs 68.2%, p = 0.04).
CONCLUSIONS: Pouch survival and functional outcomes after salvage surgery for failing ileoanal pouch was similar regardless of pouch salvage procedure. When performing redo pouch surgery, surgeons should not hesitate to construct a new pouch if indicated.
A protein from Streptococcus pyogenes, serotype M1 has been characterized. This protein, called protein SIC, plays a role in S. pyogenes pathogenicity and virulence. It inhibits hemolysis by interacting with the plasma proteins clusterin, and members of the cystatin protein super family such as histidine rich glycoprotein (HRG). The protein, comprises at least one of the following partial amino acid sequences: (a) glu thr tyr thr ser arg asn phe; (b) asp trp ser gly asp asp trp pro glu asp asp trp; (c) arg ser gly val gly leu ser gln tyr gly trp ser; (d) trp ser ser asp lys lys asp glu thr glu asp lys thr; (e) gly thr gly tyr glu lys arg asp asp trp gly gly pro gly; (f) lys arg asp asp trp arg gly pro gly his ile pro lys pro. The protein and antibodies specific for the protein can be used in analytical procedures for determining the presence of virulent Streptococcus pyogenes in a sample. The protein can also be used in vaccine compositions.
<P>PROBLEM TO BE SOLVED: To provide an Enterococcus antigen useful as a vaccine, to provide a method for obtaining the antigen, and to provide a use method of the antigen.  <P>SOLUTION: A majority of Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium) clinical isolated strains fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. The Enterococcus antigens are readily obtained from strains of Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium), and can elicit production of protective antibodies. Accordingly, the antigens are useful for vaccines which protect against infectious diseases by clinically significant (pathogenic) Enterococcus isolated strains. The antigens and antibodies generated to the antigens are also useful in diagnostic assay methods.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Primary Angle Closure Glaucoma (PACG) continues to be a major concern in Asia. It is a major cause of visual morbidity in the region1 being the most prevalent type of glaucoma especially in Chinese and Mongoloid descent.2,3 During the acute stage of the disease, prompt institution of measures to break the attack is necessary. Two recognized approaches are utilized in practice in lowering intraocular pressure and preparing for the definitive treatment of laser peripheral iridotomy. These are conventional topical and systemic medical therapy and immediate peripheral iridoplasty using either argon or diode lasers.

In the study of Lim, Tan, Chew, Seah et al., laser iridoplasty was noted to have a useful role in the management of medically unresponsive acute angle closure, particularly in those cases where laser peripheral iridotomy (PI) could not be successfully performed4 . Randomized controlled trials of Lam, Lai, Tham et al. comparing immediate laser peripheral iridoplasty plus topical medications and topical and systemic medical treatment found no significant difference in the eventual mean IOP and requirement for glaucoma medications 5 . However, significant difference in efficacy was observed between the two treatment arms within the first two hours of treatment with argon laser peripheral iridoplasty and topical medications lowering IOP faster than conventional medications6. In all the trials cited, there was no mention of sudden IOP lowering effects of either argon laser iridoplasty or conventional medications on the optic nerve head and visual field status, as well as its effect on other ocular structures like the cornea, lens and retina . In our literature search, two papers studied the optic nerve head structure and function in angle closure glaucoma, but not in the immediate period of sudden IOP lowering. Ang, Aung, Chua, Yip and Chew made a comparative assessment of the visual field loss between symptomatic and asymptomatic PACG, with 50% of asymptomatic PACG subjects presenting with end stage visual field loss in contrast to just 7% of symptomatic PACG.7 Lai, Tham, Lam et al. compared the retinal nerve fiber layer measurements of attack eyes and their fellow eyes after a single unilateral attack of acute primary angle closure (APAC) using scanning laser polarimetry six months after the acute attack8. Retinal nerve fiber layer damage was documented in eyes where the duration of the APAC attack lasted more than 48 hours8. Decompression retinopathy following laser peripheral iridoplasty for acute primary angle closure was reported in two cases reported by Lai, Lee, Leung and Chung.9 In order to compare the efficiency of laser peripheral iridoplasty and medical treatment, as well as to identify any morbidity that may come from sudden decompression of the eye, we undertake this randomized controlled trial.
In this Type 1 hybrid effectiveness-implementation three-arm parallel RCT, 375 patients with preoperative LTOU undergoing spine surgery will be recruited across 4 sites (Stanford, Harvard, Wake Forest, U. of Kansas) and randomized to 1 of 3 groups (MI-Opioid Taper and tizanidine, MI-Opioid Taper and placebo, enhanced usual care) and followed for 12 months. The primary outcome is time to baseline opioid use. Secondary outcomes are time to opioid cessation, opioid dispensing cessation, pain cessation, and risk of postoperative opioid misuse. We will examine motivation for change, change talk, and reduction in pain as mediators of treatment effects and characterize treatment interactions with participant attributes in predicting both treatment engagement and efficacy. A mixed-methods evaluation using the RE-AIM framework will explore barriers and facilitators to future larger-scale implementation of MI-Opioid Taper. The project will address the unmet needs of patients on long-term opioid use presenting for surgery in need of precision postoperative pain care to minimize opioid-related harms.
Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
BACKGROUND: Omental metastasis is the major cause of ovarian cancer recurrence and shortens patient survival, which can be largely attributed to the dynamic evolution of the fertile metastatic microenvironment driven by cancer cells. Previously, we found that adipose-derived mesenchymal stem cells (ADSCs) undergoing a phenotype shift toward cancer-associated fibroblasts (CAFs) participated in the orchestrated omental premetastatic niche for ovarian cancer. Here, we aim to elucidate the underlying mechanisms.
METHODS: Small extracellular vesicles were isolated from ovarian cancer cell lines (ES-2 and its highly metastatic subline, ES-2-HM) and patient ascites using ultracentrifugation. Functional experiments, including Transwell and EdU assays, and molecular detection, including Western blot, immunofluorescence, and RT-qPCR, were performed to investigate the activation of ADSCs in vitro. High-throughput transcriptional sequencing and functional assays were employed to identify the crucial functional molecules inducing CAF-like activation of ADSCs and the downstream effector of miR-320a. The impact of extracellular vesicles and miR-320a-activated ADSCs on tumor growth and metastasis was assessed in subcutaneous and orthotopic ovarian cancer xenograft mouse models. The expression of miR-320a in human samples was evaluated using in situ hybridization staining.
RESULTS: Primary human ADSCs cocultured with small extracellular vesicles, especially those derived from ES-2-HM, exhibited boosted migration, invasion, and proliferation capacities and elevated α-SMA and FAP levels. Tumor-derived small extracellular vesicles increased α-SMA-positive stromal cells, fostered omental metastasis, and shortened the survival of mice harboring orthotopic ovarian cancer xenografts. miR-320a was abundant in highly metastatic cell-derived extracellular vesicles, evoked dramatic CAF-like transition of ADSCs, targeted the 3'-untranslated region of integrin subunit alpha 7 and attenuated its expression. miR-320a overexpression in ovarian cancer was associated with omental metastasis and shorter survival. miR-320a-activated ADSCs facilitated tumor cell growth and omental metastasis. Depletion of integrin alpha 7 triggered CAF-like activation of ADSCs in vitro. Video Abstract CONCLUSIONS: miR-320a in small extracellular vesicles secreted by tumor cells targets integrin subunit alpha 7 in ADSCs and drives CAF-like activation, which in turn facilitates omental metastasis of ovarian cancer.
An iron/oligopeptide compound coated iron oxyhydroxide nano shuttle prepared in aqueous solution and a preparation method thereof belong to the technical field of biomedical materials. The method comprises the step of reacting water-soluble ferric salt with water-soluble amino acid in an aqueous solution to obtain a water-phase-dispersed spindle-shaped nano material with ferric hydroxide as a core and an iron/oligopeptide compound as a shell. According to the method, biologically safe iron salt and amino acid are used as raw materials, the thickness of the shell layer of the iron/oligopeptide compound is adjustable, the type of oligopeptide can be controlled by different types of amino acid, the experimental repeatability is good, and the method is suitable for batch production. The spindle-shaped nanometer material modified by the surface oligopeptide can be selectively taken up by tumor cells, and the taking amount of normal cells is less. The composite nano shuttle can be disintegrated under the action of a tumor microenvironment, a large number of iron ions in the structure are released, and the tumor growth is inhibited through an iron death mechanism. In addition, the composite nano shuttle can be used as a carrier to further load medicines and can be used as a magnetic resonance imaging contrast agent.
PCT No. PCT/EP94/02087 Sec. 371 Date Feb. 28, 1995 Sec. 102(e) Date Feb. 28, 1995 PCT Filed Jun. 28, 1994 PCT Pub. No. WO95/01375 PCT Pub. Date Jan. 12, 1995A protein isolated from crude extracts of Hirudo medicinalis is disclosed, which strongly inhibits the binding to collagen of platelets and their subsequent activation, which leads to platelet aggregation and thrombus formation. Additionally the protein prevents binding of von Willebrand factor to collagen. Described is a method for isolation and purification of the protein as well as its use for blocking collagen-stimulated platelet aggregation. The new protein (Brandinin) has a molweight of approximately 15 kD, binds to collagen but has no collagen-cleaving activity. The protein is useful in the prophylaxis, prevention and treatment of thrombotic diseaeses and for coating of blood-contacting materials, rendering them thromboresistant.
Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
Chronic insomnia is one of the most common symptoms that individuals experience during a major depressive episode. Insomnia may lead to increased risk for recurrence of major depression, as well as poor quality of life and increased risk of suicide. Studies have shown that treating insomnia during a major depressive episode may not only help reduce symptoms of major depression during the day, but also improve an individual's general quality of life. Thus, sleeping pills, also known as hypnotics, are commonly prescribed for people with psychiatric disorders. However, little is known about the safety and efficacy of combining sleeping pills with antidepressant medications. This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.

Participants in this double-blind study will first receive fluoxetine, an antidepressant medication, for 1 week. Participants whose symptoms of insomnia subside after this initial week will continue on fluoxetine for the duration of the study and will not receive sleeping pills. Those who do not experience an improvement in their symptoms of insomnia after 1 week will be randomly assigned to receive either placebo or eszopiclone, which is a sleeping pill, in addition to fluoxetine. All treatments will be given for 8 weeks. Participants will attend study visits at various points throughout the treatment phase. Follow up visits will occur periodically over the next 4 months. Assessments will include physiological measures during sleep, mood, suicidal thinking, quality of life and actigraphy, which measures the amount of movement during sleep.
Deep learning technology has been widely adopted in the research of automatic arrhythmia detection. However, there are several limitations in existing diagnostic models, e.g., difficulties in extracting temporal information from long-term ECG signals, a plethora of parameters, and sluggish operation speed. Additionally, the diagnosis performance of arrhythmia is prone to mistakes from signal noise. This paper proposes a smartphone-based m-health system for arrhythmia diagnosis. First, we design a cycle-GAN-based ECG denoising model which takes real-world noise signals as input and aims to produce clean ECG signals. In order to train its two generators and two discriminators simultaneously, we explore an unsupervised pre-training strategy to initialize the generator and accelerate the convergence speed during training. Second, we propose an arrhythmia diagnosis model based on the time convolution network (TCN). This model can identify 34 common arrhythmia events using eight-lead ECG signals, and we deploy such a model on the Android platform to develop an at-home ECG monitoring system. Experimental results have demonstrated that our approach outperforms the existing noise reduction methods and arrhythmia diagnosis models in terms of denoising effect, recognition accuracy, model size, and operation speed, making it more suitable for deployment on mobile devices for m-health monitoring services.
An scFv peptide comprising a V H  domain and a V L  domain linked by an amino acid spacer is disclosed. The V H  domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64. The V L  domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 66. The scFv peptide also comprises the substitution or deletion of an amino acid in the V H  domain at the position corresponding to C 28 .
There is provided by this invention a novel method of preparing Gram-negative bacterial vaccines. The method comprises providing a concentrated Gram-negative bacterial antigenic preparation, adsorbing the preparation with a mineral carrier capable of binding free-endotoxin in the antigenic preparation in an amount effective to produce optimal binding of endotoxin and antigen and diluting the adsorbed preparation for use in a vaccine. Also provided by this invention is a vaccine produced by the method of this invention. Also provided by this invention is a Gram-negative bacterial vaccine wherein the improvement comprises a concentration of mineral carrier in the vaccine which is less than 5.0 % v/v. Also provided by this invention is a Gram-negative bacterial vaccine comprising a mineral carrier wherein the amount of the mineral carrier in the vaccine has been predetermined by the method of this invention. Also provided by this invention is a method of vaccinating an animal against Gram-negative bacterial infections comprising administering to the animal an effective amount of a vaccine of this invention.
PURPOSE: To obtain a new compound useful as a fragrance component having a roast-like fragrance and flavor characteristics with an excellent durable sweet feeling. CONSTITUTION: The 1-ethylpyrrole-2-carboxylic acid ester is shown by the formula (R is H or ethyl; R<1> is a 1-2C alkyl. This compound is obtained by reacting a 1-ethylpyrrole with n-butyllithium in an organic solvent (e.g. THF) and then with a corresponding halogenated formic ester. The amount of the n-butyllithium used is 1-3mols an that of the halogenated formic ester is 1-5mols based on 1mol of the 1-ethylpyrrole. The compound is used as an active ingredient to give a perfume composition, which is used to give foods and beverages provided with unique fragrance and flavor.
The instant invention disclosed the method of alleviating psoriasis symptoms comprises administering 11-cis-retinoic acid, in an acceptable topical vehicle, directly to psoriasis involved areas of the body. The retinoic acid has a concentration of the 11-cis isomer of at least 10 % of the level of all the isomers, on a weight basis. The 11-cis-retinoic acid can be the reaction product of the ultraviolet illumination of a second geometric isomer of retinoic acid which differs from the 11-cis-retinoic acid only in the cis-trans isomer state of at least one of its four non-ring C=C double bonds. The second isomer of retinoic acid is one of the following: all-trans; 7-cis; 9-cis; 13-cis; 7,9-dicis; 7,11-dicis; 9,11-dicis; 9,13-dicis; or 11,13-dicis. Alternatively, 11-cis retinoic acid is the reaction product of 11-cis retinaldehyde or 11-cis retinal with oxidizing agents such as hypochlorite and resorcinol or mixtures thereof as oxidizing agents. The topical vehicle includes at least one member selected from the group consisting of water, propylene glycol, petrolatum, mineral oil, glycerin, and mixtures thereof.
PURPOSE: To obtain microcapsules having a slowly releasing property by soaking a capsule membrane which is dehydrated and has selective permeability into an aqueous soln. of a specific concn. of a solute to diffuse the soln. in an internal space thereof. CONSTITUTION: The membrane comprising polyvinylamine, aminated polysaccharide, polyaminated polypeptide or the like and having selective permeability is dehydrated and deflated to preliminarily mold capsules. As a dehydrating agent, an organic solvent such as ethanol and methanol or an aqueous soln. of high osmotic pressure is used and the microcapsules are washed by these solutions to be dehydrated. These dehydrated and deflated capsules are soaked in a large quantity of a soln. containing chemically active substances such as medicine, hormone and vitamin to charge the active substances in an internal space thereof. Microcapsules slowly releasing useful substances can be efficiently obtained by the method described above.
Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated.